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Executive Summary
The Dr. Robert Bree Collaborative was established in 2011 to provide a forum in which public and
private health care stakeholders can work together to improve quality, health outcomes, and costeffectiveness of care in Washington State. Alzheimer’s disease and other dementias are a growing
concern in Washington State and around the country. The complex symptoms including in memory,
cognition, and social functioning are difficult for patients themselves, their family members and friends,
and the health care system at large. In many cases no clear guidelines exist to support the patient
through diagnosis and increase in symptoms. The Bree Collaborative elected to address this topic and
convened a workgroup to develop recommendations that met from January 2017 to November 2017.
This Report and Recommendations has six focus areas developed in partnership with the Dementia
Action Collaborative:
1.
2.
3.
4.
5.
6.

Diagnosis,
Ongoing care and support,
Advance care planning and palliative care,
Need for increased support and/or higher levels of care,
Preparing for potential hospitalization, and
Screening for delirium risk.

The goal of the recommendations are to support patients, their family members, and other caregivers
across the disease process. The workgroup developed a roadmap for implementation starting on page 5
outlining the patient perspective for optimal care alongside operational details for each of the six areas
walking through the current state, intermediate steps toward implementation of the recommendations,
and a description of optimal care. Following this on page 12 are specific steps for stakeholder groups
including: patients and family members, primary care practices and systems (including primary care
providers), health plans, hospitals, skilled nursing facilities, and Washington State agencies to improve
quality of dementia care, health outcomes of people with dementia and their caregivers, and
affordability.
The remainder of this Report is meant to support these six focus areas including discussions of the
evidence and best practices for diagnosis, how to best support patients and families through disease
progression, linking these recommendations to earlier Bree Collaborative work around advance care
planning and palliative care, and information on transitions of care and delirium. The Report also
discusses other work within Washington State to facilitate high-quality dementia care including
development of the Washington State Plan to Address Alzheimer's Disease and Other Dementias and
ending with an inclusion of dementia-specific measures.

Adopted by the Bree Collaborative, November 15, 2017.
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Dr. Robert Bree Collaborative Background
The Dr. Robert Bree Collaborative was established in 2011 by Washington State House Bill 1311 “…to
provide a mechanism through which public and private health care stakeholders can work together to
improve quality, health outcomes, and cost effectiveness of care in Washington State.” The Bree
Collaborative was modeled after the Washington State Advanced Imaging Management (AIM) project
and named in memory of Dr. Robert Bree, a pioneer in the imaging field and a key member of the AIM
project.
Members are appointed by the Washington State Governor and include public health care purchasers
for Washington State, private health care purchasers (employers and union trusts), health plans,
physicians and other health care providers, hospitals, and quality improvement organizations. The Bree
Collaborative is charged with identifying up to three health care services annually that have substantial
variation in practice patterns, high utilization trends in Washington State, or patient safety issues. For
each health care service, the Bree Collaborative identifies and recommends best-practice, evidencebased approaches that build upon existing efforts and quality improvement activities to decrease
variation. In the bill, the legislature does not authorize agreements among competing health care
providers or health carriers as to the price or specific level of reimbursement for health care services.
Furthermore, it is not the intent of the legislature to mandate payment or coverage decisions by private
health care purchasers or carriers.
See Appendix A for a list of current Bree Collaborative members.
Recommendations are sent to the Washington State Health Care Authority for review and approval. The
Health Care Authority (HCA) oversees Washington State’s largest health care purchasers, Medicaid and
the Public Employees Benefits Board Program, as well as other programs. The HCA uses the
recommendations to guide state purchasing for these programs. The Bree Collaborative also strives to
develop recommendations to improve patient health, health care service quality, and the affordability of
health care for the private sector but does not have the authority to mandate implementation of
recommendations.
For more information about the Bree Collaborative, please visit: www.breecollaborative.org.
Alzheimer’s disease and other dementias are a growing concern in Washington State and around the
country. The complex symptoms including memory, cognition, and social functioning are difficult for
patients themselves, their family members and friends, and the health care system at large. In many
cases no clear guidelines exist to support the patient through diagnosis and increase in symptoms. The
Bree Collaborative elected to address this topic and a workgroup convened to develop
recommendations from January 2017 to November 2017.
See Appendix B for the Alzheimer’s Disease and Other Dementias workgroup charter and a list
of members.
See Appendix C for results of the Guideline and Systematic Review Search Results.

Adopted by the Bree Collaborative, November 15, 2017.
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Purpose Statement
The decline in memory and other cognitive functions and corresponding loss of independence because
of dementia is a growing concern in our aging population. Age is the biggest risk factor for dementia
with prevalence rates of 13.9% in those 71 and older increasing to 37.4% for those 90 and older.1 The
majority of cases, 69.9%, are due to Alzheimer’s disease with vascular dementia (also known as poststroke dementia) accounting for 17.4% and the remaining 12.7% due to a combination of Parkinson’s
dementia, normal-pressure hydrocephalus, frontal lobe dementia, alcoholic dementia, traumatic brain
injury, Lewy body dementia, or being of unknown origin.1 Hearing loss, associated with increasing age, is
also associated with cognitive decline and increased risk of dementia.2 Washington State has the third
highest rate of death from Alzheimer’s disease of any state and Alzheimer’s is the third highest ageadjusted cause of death within the State overall.3 The number of people diagnosed with dementia is
expected to increase 40% in next 10 years and 181% over the next 30 years.3
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) defines dementia as
decline from previous level of performance in learning and memory, language, executive function,
complex attention, perceptual-motor, and/or social cognition that interfere with independence in
everyday activities absent another cause (e.g., depression, in the context of delirium).4 Dementia can
impact ability to plan and carry out activities, manage work and personal finances, and take
medications.5 Severe dementia is associated with greater prevalence of behavioral and psychological
symptoms including agitation, anxiety, depression, delusions, and sleep or appetite changes.6 These
behavioral and psychological symptoms are complex and can be the most difficult for family members
and other caregivers.7 Dementia also can result in a higher risk of falls at home, hospitalizations, and risk
of falls within a hospital setting.8.9 Dementia is associated with higher out of pocket expenses, that
increase with the severity of the diagnosis, especially for hospital or nursing home care and prescription
medications.8,9 Additionally, dementia is a terminal condition that lends itself well to palliative care
services.

In many practices in Washington State, there are no guidelines to increase quality of
care for diagnosis or care for patients with Alzheimer’s disease and other
dementias.10 This is costly to the health care system and overly burdensome to
primary care clinicians, and patients, their caregivers, and the community.
The Bree Collaborative Alzheimer’s Disease and Other Dementias Workgroup endorses and aims to build
off the previous work within Washington State, specifically the Washington State Plan to Address
Alzheimer's Disease and Other Dementia. The workgroup aims to align care delivery with the existing
evidence-based standard of care for each stage of disease and across health care settings for both for
patients and their families and caregivers. The workgroup seeks to address the variation in quality of
treatment across the state of Washington through implementation of these standards and build a health
care system that is responsive to individual patient and family need as well as being equitable.

Adopted by the Bree Collaborative, November 15, 2017.
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Recommendations
The Bree Collaborative Alzheimer’s Disease and Other Dementias workgroup has developed
recommendations in six areas: (1) diagnosis, (2) ongoing care and support, (3) advance care planning
and palliative care, (4) need for increased support and/or higher levels of care, (5) preparing for
potential hospitalization, and (6) screening for delirium risk. This recommendation is developed in
partnership with the Dementia Action Collaborative and seeks to build off the work of the health and
medical subcommittee. Alzheimer’s disease and other dementias occur in all cultural and ethnic groups
and must be addressed in a culturally-sensitive manner.
The workgroup defines dementia as outlined by the National Institute on Aging and the Alzheimer’s
Association including symptoms that:11


“Interfere with the ability to function at work or at usual activities; and



Represent a decline from previous levels of functioning and performing; and



Are not explained by delirium or major psychiatric disorder;



Cognitive impairment is detected and diagnosed through a combination of (1) history-taking from the
patient and a knowledgeable informant and (2) an objective cognitive assessment, either a “bedside”
mental status examination or neuropsychological testing. Neuropsychological testing should be performed
when the routine history and bedside mental status examination cannot provide a confident diagnosis



The cognitive or behavioral impairment involves a minimum of two of the following domains
o Impaired ability to acquire and remember new information––symptoms include: repetitive
questions or conversations, misplacing personal belongings, forgetting events or appointments,
getting lost on a familiar route.
o Impaired reasoning and handling of complex tasks, poor judgment––symptoms include: poor
understanding of safety risks, inability to manage finances, poor decision-making ability, inability
to plan complex or sequential activities.
o Impaired visuospatial abilities––symptoms include: inability to recognize faces or common
objects or to find objects in direct view despite good acuity, inability to operate simple
implements, or orient clothing to the body.
o Impaired language functions (speaking, reading, writing)––symptoms include: difficulty thinking
of common words while speaking, hesitations; speech, spelling, and writing errors.
o Changes in personality, behavior, or comportment–– symptoms include: uncharacteristic mood
fluctuations such as agitation, impaired motivation, initiative, apathy, loss of drive, social
withdrawal, decreased interest in previous activities, loss of empathy, compulsive or obsessive
behaviors, socially unacceptable behaviors.”

We found it helpful to ground all six focus areas in the patient perspective to keep the patient at the
center of care improvement. On the following pages we outline the patient perspective alongside
operational details for each of the six areas walking through the current state, intermediate steps
toward implementation of the recommendations, and a description of optimal care.
Following this on page 12 are specific steps for stakeholder groups including: patients and family
members, primary care practices and systems (including primary care providers), health plans, hospitals,
skilled nursing facilities, and Washington State agencies to improve quality of dementia care, health
outcomes of people with dementia and their caregivers, and affordability.
Adopted by the Bree Collaborative, November 15, 2017.
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Table 1: Recommendations for Optimal Alzheimer’s Disease and Other Dementia Care
Focus Area
1 Diagnosis

Patient Perspective
I or my family members
have concerns about
memory. My care team
talks with me about my
concerns and helps me
understand the cause of
any trouble with thinking
ability. I know who to
contact in case of urgent
questions or situations
and have thought about
the type of care that I
would want at different
stages of the disease.

Operational Details
Current State: While some providers may routinely screen for or discuss cognitive issues with
patients, in many cases issues with memory and cognition are only addressed if they are
brought up by the patient or family member(s). Once brought up by the patient or family
member, issues with memory or cognition may be adequately addressed by the provider. In
some cases there may be no clinical follow-up. The provider may be unsure as to screening
tools, how to utilize the Medicare Annual Wellness Visit, or next steps and may not feel
comfortable discussing cognitive issues due to lack of training and lack of a system-wide
protocol for addressing cognitive concerns. Primary care providers may diagnose dementia or
may refer to a specialist (i.e., neurologist, geriatric psychiatrist) for diagnosis if one is available
within the health care system. Specialty consultation may be unavailable.
Intermediate Steps: Practices work to increase providers’ level of comfort and expertise in
diagnosing and discussing a dementia diagnosis, increasing understanding that this diagnosis is
within the primary care scope of practice. Clear guidelines are available on how to make the
diagnosis using validated tools with the expectation that the provider will truthfully discuss the
diagnosis with the patient and family and record the diagnosis in the medical record. Practices
may pilot screening programs with select populations, reporting on lessons learned before
implementing wider screening. Primary care providers involve a neurologist or other specialist
as needed for consultation and support or for differential diagnosis.
Optimal Care:






Adopted by the Bree Collaborative, November 15, 2017.

The patient has an identified primary care provider.
Patient and family members receive coordinated care as part of an interdisciplinary
team that has been trained in how to talk about cognitive impairment. This may
include support staff in the primary care provider office, specialists such as neurology
consultation, and community partners.
Family members or other caregivers are included in conversations and feel supported
and heard.
Primary care providers are clear on the value of early detection and feel comfortable
truthfully discussing cognitive issues, understanding the uncertainty that can
accompany the diagnosis. Mild cognitive impairment (MCI) or dementia is detected at
an early stage.
Page 5 of 40




2 Ongoing Care and
Support/Manage
ment

Once I have a diagnosis, I
and my family members
feel hopeful that we/I can
manage my cognitive
diagnosis with my care
team and family
member(s).

Hearing loss is assessed and appropriately addressed (e.g., hearing aids, personal
amplifiers) as hearing loss can complicate identification and treatment.
Diagnosis follows a two-stage clear clinical protocol with initial screening through the
Medicare Annual Wellness visit or other visit in which cognitive impairment is detected
with a brief (<5 minutes), validated tool. Direct observation with consideration of
information obtained by family members, friends, or others may also be used.
o A positive finding is followed by additional evaluation and confirmation of the
diagnosis, if needed. Diagnosis follows the Alzheimer’s Association Medicare
Annual Wellness Visit Algorithm for Assessment of Cognition outlined in
Appendix D and in a Clinical Provider Practice Tool outlined here.
o The diagnosis conversation and any subsequent conversations follow the
Alzheimer’s Association principles for a dignified diagnosis, listed in Appendix
E, and includes an advance care planning conversation (see #4). CPT code
99483 (i.e., detailed structural assessment of dementia or Alzheimer’s disease
performed by a clinician that cannot be done the same day as an office visit)
can be billed for care planning services provided to individuals with cognitive
impairment.

Current State: Patients experience significant variability in the type and number of
interventions and support offered after diagnosis and throughout the disease course. Patients
and families are not consistently informed of treatment options, community services, or an
answer to the question “I have a diagnosis, what do I do now?” and can feel lost. Providers
may be unaware of the supports available in their community or there may be a lack of
community support and providers are uncertain as to next steps.
Intermediate Steps: The practice has a pilot pathway for interventions and supports to offer at
different stages throughout the disease process that may not be used for all appropriate
patients. Family and caregivers may be part of the initial conversation, but may not feel
supported throughout the disease process.
Optimal Care:


Adopted by the Bree Collaborative, November 15, 2017.

Patients are often best supported by a care team framework. The care team may
include providers outside of the practice (e.g., specialty care). Patients and family
members are included as part of the care team with patient goals and values being
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incorporated into the type of interventions offered as well as consideration for
comorbid conditions.
Primary care teams routinely assess complexities of supporting patients with dementia
and the needs of family care partners for enhanced support.
Dementia care management services (e.g., home health, phone-support, enhanced
outpatient management) are offered to patients or caregivers who have been
determined to be high-risk. This high-risk group may include patients that have several
medical comorbidities, complex medication regiments, behavioral/psychiatric
symptoms, and/or history of frequent utilization of acute care services. Care
management services to consider may include: comprehensive in-home assessment by
trained health care professionals; collaborative goal-setting between clinicians, care
partners and patients; close follow-up and coordination of medical and psychosocial
services and routine assessment of needs.
Providers routinely consider a patient’s dementia diagnosis and comorbid conditions
when making decisions to minimize unnecessary or harmful care. Providers
appropriately treat conditions that can worsen symptoms or lead to poor outcomes,
including depression and existing medical issues.
The care team is able to maximize functioning to meet patient and family needs at
each stage of the disease.
Evidence-based interventions (e.g., exercise, diet modification) are suggested upon
diagnosis and discussed during any follow-up visits. The care team assess and discusses
with the patient and family how to reduce risk of falls, how to optimize function and
mitigate confusion, how to manage medication(s), and how to address driving status
and safety (outlined here).
The level of support offered depends on patient-factors including complexity, severity,
level of caregiver support, and other factors.
Neuropsychiatric symptoms (e.g., agitation, psychosis) may be due to social,
psychological, or environmental factors and management should be discussed using a
shared-decision making approach. Non-pharmacologic approaches are best attempted
first; pharmacological therapies are not a first line therapy.
Patients and families are offered information about available community supports
such as through the Alzheimer’s Association and local Area Agency on Aging programs.
Patient quality of life is maximized through a focus on individuals’ preserved
capabilities and identities, access to services that prolong functioning (e.g., speech,
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3 Advance Care
Planning and
Palliative Care

I have had a meaningful
conversation with my
doctor, including my
family member(s), about
what I want for end-of-life
care. We have written this
down into an advance
directive that is accessible
by my care team and
family. I feel confident
that my goals of care will
be followed. If I need it, I
have access to and
understand the need for
palliative care.

Current State: Care given to patients at the end of life varies based on institutional protocol
and is not necessarily aligned with patient goals of care. Family and other caregivers may feel
burdened in making clinical decisions without having had previous conversations with the
patient and feel overwhelmed and unsupported. Patient symptoms (e.g., pain) may not be
well-managed or addressed. Non-value added care may be provided, such as mammograms or
feeding tube placement in patients with advanced dementia.
Intermediate Steps: Patient and family members have begun to have conversations about
goals for care but may not have had these in a clinical setting and have not documented their
goals in an advance directive or the advance directive is not accessible to the care team.
Optimal Care:





Adopted by the Bree Collaborative, November 15, 2017.

occupational, physical therapies hearing aids or personal amplifiers), and continued
engagement with social networks and enriching activities, through use of a strengthsbased approach.
Caregivers are supported and providers assess and note caregiver knowledge, skills,
capacity and possible distress at each visit. Caregivers are also connected with
resources such as county Family Caregiver Support Programs, which facilitate access to
respite care, and support groups, if available.

Patients, providers, family, and other caregivers have had a comprehensive advance
care planning conversation in a clinical setting that has been documented in an
advance directive as early as possible to maximize the patient’s voice and input. This
stipulates specific treatment preferences (if known and applicable to the situation), a
durable power of attorney for health care that names a surrogate and indicates the
amount of leeway the surrogate should have in decision-making; a written personal
statement that articulates the patient’s values and goals regarding end-of-life care;
discussion of risks, benefits, and goals for a potential hospitalization; and Physician
Orders for Life Sustaining Treatment (POLST).
Providers routinely consider patient’s dementia diagnosis and issues of decisionmaking capacity when making decisions to minimize unnecessary or harmful care and
discuss this with the patient and family.
The care team has discussed when palliative care and/or hospice might be
appropriate.

Page 8 of 40


4 Need for
Increased Support
and/or Higher
Levels of Care

I and my family members
have a plan if my cognitive
decline and care is more
than can be managed
safely at home with my
current supports.

The patient and family know who to contact if symptoms (e.g., pain) develop or
worsen and feel confident in their care plan.

Current State: For most patients and families there is little information about planning for
possible transitions to higher levels of care. Providers and care teams may be unsure as to
community supports available to patients and families and not know how to identify proactive
steps to take (e.g., additional home support, residential care).
Intermediate Steps: Initial conversations about the diagnosis include information about
progression of cognitive decline and changes in functional abilities. Patients and family
members are encouraged to start thinking about potential need for higher levels of care at
home or in an alternative living situation. Patients and families are connected to community
resources that provide education about these care options and understand how to manage
behavioral symptoms as much as possible.
Optimal Care:
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Patients and family members understand that they may face decisions about the need
for increased care, care transitions and/or increased stress and caregiver burden.
Patients and families have these conversations early on in the disease, anticipating
progression and have a plan if care needs are greater than can be safely managed at
home with current supports, such as additional in-home care or services, respite care,
or move to a residential facility.
From the time of initial diagnosis, patients and family members are connected to
community resources that can help plan for future and increasing care needs.
Monitoring for progression of cognitive decline, emergence of behavioral symptoms,
functional impairment (e.g., activities of daily living), and care-partner/family capacity
is part of each primary care visit and communicated to the patient and family
members.
Planning includes consideration for caregiver stress and capacity, financial and
insurance concerns (e.g., long term care coverage), health care considerations, and
availability of local residential facilities, paid caregivers, and community resources
(such as Meals on Wheels, volunteer chore services, etc.).
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5 Preparing for
Potential
Hospitalization

I and my family
understand that I may
need to receive care from
a hospital and have
planned ahead for a
potential hospital visit.
After leaving the hospital,
I and my family know our
next steps – whether that
is continuing to live at
home or receiving care at
a residential facility – and
have enough information
to make a decision
comfortably.

Current Care: Hospitalization or a visit to an emergency room may feel unexpected to patients
and family members. Clinicians and hospital staff may be unaware of the dementia diagnosis
or any patient communication issues and may be unprepared for preventing patient safety
issues such as agitation, delirium or adverse reactions to medications. At discharge, patients
and families may feel unsupported in managing symptoms at home or unsure about transitions
to residential care or a rehabilitation facility.
Intermediate Steps: Patients and families begin to have conversations about how to plan and
prepare for a potential hospitalization. Hospitals have plans on how to incorporate relevant
personal information (e.g., dementia diagnosis) into the electronic health record (EHR),
procedures performed and care provided during the hospitalization (e.g., anesthesia and pain
protocols), and how to communicate this diagnosis to staff. Discharge protocols identify family
caregivers and take into consideration needs of patients with dementia and how to support
patients either being discharged to home or to a residential care facility.
Optimal Care:
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Patients and family members have had conversations early on in the disease process to
address patient wishes for hospital visits and medical intervention including risks and
benefits of hospitalization. This may include using a POLST.
Family and other caregivers understand red flags that may necessitate entry into an
acute care setting and understand how to implement the previously developed care
plan if the patient is unable to express his or her wishes.
All treating clinicians and other staff are aware of the dementia diagnosis and
understand the patient’s communication ability, ability to hear, behavioral concerns
(e.g., agitation, exit seeking, wandering), and other information that the patient may
not be able to communicate (e.g., allergies, other reactions to medications, dietary
preference).
At discharge, the patient and family members are supported whether the patient is
going home, to their prior facility, or to a residential care facility. Discharge planners
facilitate discharge to the most appropriate location given an assessment of the
patient’s current status (which may have changed since hospitalization), care partner
or facility’s ability to meet needs, and rehabilitation potential.
The hospital team communicates with the facility or caregiver discharge instructions,
current medications, and follow-up appointment needs.
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6 Screening for
Delirium Risk

In a hospital, my care
team asks me questions to
see whether confusion and
lack of independence will
be an issue, especially
after surgery. I understand
what this might mean for
me and my recovery.

Adopted by the Bree Collaborative, November 15, 2017.

Current Care: Screening for delirium or incorporation of a patient’s dementia diagnosis into
the medical record is not a routine part of hospital care.
Intermediate Steps: Practices and hospitals may develop a pilot project to incorporate
screening for delirium into a specific pre-surgical care pathway (e.g., total joint replacement)
with eventual plans to learn from implementation and spread the protocol to all admissions.
Optimal Care:
 During hospitalization, all patients 65 years of age or older or with other identifiable
risk factors are screened for risk of delirium. Results are incorporated into the medical
record and the care team is aware of risk.
 The patient as well as their family and other caregivers are made aware of the risk of
delirium, what symptoms might look and feel like, and what delirium might mean for
recovery.
 Hospitals and providers implement care plans and protocols to minimize risk for
delirium and have established plans to respond appropriately when it occurs.
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Recommendations for Stakeholder Actions and Quality Improvement Strategies
Persons with Memory Loss and Family Members
Diagnosis











Talk to your health care providers about any concerns you might have about memory or thinking
ability. Your care team should ask you a standard set of questions and may set up a follow-up
appointment.
Talk to your health care providers about any concerns you have about being able to hear. If you
do have hearing impairment, talk about hearing aids or an assisted listening device (e.g., pocket
talker).
o Information on identifying symptoms of hearing loss here
o Information on how to communicate with someone who has hearing loss here
Make sure you can identify your primary care provider or family doctor.
Review the resources developed by the Washington State Dementia Action Collaborative
especially the Dementia Road Map: A Guide for Family and Care Partners. This tool takes
patients and caregivers in all stages of cognitive decline through action steps and questions from
the early stages of being worried and wondering to late-stage dementia.
During diagnosis we recommend that your health care provider follow the principles outlined in
the Alzheimer’s Association’s Principles for a Dignified Diagnosis. You can see these principles
that have been developed by patients here and also listed in Appendix E on page 36.
Ask your care team about local resources. Connect to others in your community who may be
going through the same process. Some resources include:
o The county’s Area Agency on Aging provider (including referrals for family and caregiver
support such as respite care facilities)
o African American Elders Program
o Alzheimer’s Association of Washington State
o Alzheimer Society of Washington
o American Association of Retired Persons (AARP)
o American Automobile Association (AAA) Senior Drivers
o Chinese Information and Service Center
o Community Living Connections including resources by county
o Hearing Loss Association of America - Washington State Association (HLA-WA)
o Momentia Seattle
o National Institute on Aging
o Open Doors for Multicultural Families
o Seattle Indian Health Board
o Path with Art
o Washington State Department of Social and Health Services - Office of the Deaf and
Hard of Hearing

Adopted by the Bree Collaborative, November 15, 2017.
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Ongoing Care and Support/Management




Talk with your care team about how to maintain quality of life and what this means to you and
your family. Including concerns about:
o Progression of cognitive decline
o Managing other diagnoses that you might have (e.g., diabetes, high blood pressure,
hearing loss)
o Driving status and safety (outlined here)
o Home safety and risk of falls
o Feeling down or depressed
o Confusion, agitation, aggression, and/or wandering
o Sleep quality and sleep disturbance
o Managing medications
o Ability of your care partner/family to meet your care needs now and in the future
o Whether palliative care or hospice might be appropriate
o Any other concerns
Consider lifestyle changes as recommended by your care team (e.g., cardiovascular exercise,
mindful changes to diet).

Advance Care Planning. Think about the type of care you would want at the end of life. Have a
conversation with your family members or other caregivers about what you would want. You should
also have a conversation with your care team about your wishes, goals, and values for end-of-life care
that includes caregivers and the individual designated as your durable power of attorney for health care.




You should complete:
o An advance directive that stipulates specific treatment preferences (if known and
applicable to the situation),
o A durable power of attorney for health care that names a surrogate and indicates the
amount of leeway the surrogate should have in decision-making, and
o A written personal statement that articulates your values and goals regarding end-of-life
care.
o Physician Orders for Life-Sustaining Treatment (POLST)
There are many resources out there to help people have this conversation including:
o Alzheimer’s Association End-of-Life Decisions (specific to dementia)
o Death Over Dinner
o The Conversation Project (specific to dementia)
o End of Life Washington – Alzheimer’s Disease/Dementia Mental Health Advance
Directive
o Five Wishes
o Honoring Choices Pacific Northwest
o US National Library of Medicine Medline Plus

Adopted by the Bree Collaborative, November 15, 2017.
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Planning for Higher Care Needs and Hospitalizations














Have conversations early on in disease progression about your wishes for hospital visits and
medical intervention. Conversations should include risks and benefits of hospitalization and may
include filling out a Physician Order for Life Sustaining Treatment also known as POLST. As part
of these conversations, think about the type of care that you would not want (e.g., feeding
tubes). Information from Choosing Wisely and Consumer Reports on feeding tubes can be found
here.
Write down your wishes into a care plan with family and other caregivers. Talk about how family
members or other caregivers should implement the care plan if you are unable to express your
wishes.
Be sure that you and your family or other caregivers understand red flags that may mean you
need to go to the hospital and under what conditions you may not want to receive care in the
hospital setting.
Talk about the potential need for a higher level of care (e.g., more help at home) if care needs
are greater than can be safely managed. Conversations should include financial as well as
medical concerns.
Connect to community resources or state resources that can help plan for future and increasing
care needs including respite care.
Discuss palliative care with your care team as well as whether or not hospice care might be
appropriate.
Pack an emergency bag that can help make a hospitalization less stressful. This “to go” bag
might include:12
o Copies of insurance cards
o List of medical conditions, medications, and allergies
o Your primary care provider’s name and contact information
o Your advance directive or POLST order
o Other personal information such as name and preferred language, need for glasses,
dentures, or hearing aids.
o Snacks or water
o Incontinence briefs, if usually worn, moist wipes, and plastic bags
o Comforting objects or music player with earphones
o A change of clothing, toiletries, and personal medications for yourself
o Pain medicine, such as ibuprofen, acetaminophen, or aspirin—a trip to the emergency
room may take longer than you think, and stress can lead to a headache or other
symptoms
o A pad of paper and pen to write down information and directions given to you by
hospital staff
o A small amount of cash
o A note on the outside of the emergency bag to remind you to take your cell phone and
charger with you. More information here.
Caregiving can be stressful. Talk to your provider about your needs as a caregiver. More
information here.
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Primary Care Practices and Systems (including Primary Care Providers)
Review Table 1
Diagnosis


Identify the patient’s primary care provider and be sure the patient and family members know
who this is.



Provide care as part of an interdisciplinary team where all members have been trained in how to
talk about a dementia diagnosis that is tailored to the patient’s individual and cultural needs and
goals of care including language. This may include support staff in primary care provider office,
specialists such as neurology consultation, and community partners. The patient and family or
other caregivers should be included as part of the care team and supported along with the
patient.



Assess for and appropriately address hearing loss (e.g., hearing aids, personal amplifiers).
Hearing loss can complicate dementia identification and treatment.



When talking to patients and family members, follow the Alzheimer’s Association’s Principles for
a Dignified Diagnosis in Appendix E. Be truthful about any diagnosis. At the patient’s request,
purposefully include family members or other caregivers in any conversation and work to be
sure they feel supported and that their concerns are heard as well as those of the patient.



Work with information technology, billing/coding and other practice resources to add the CPT
code 99483 to your electronic health record and learn how to use it. More information here.
o Information on Medicare’s Cognitive Impairment Assessment and Care Planning Code,
CPT code 99483 (Alzheimer’s Association Expert Task Force Recommendations and Tools
for Implementation) here.
o Information including tools and instructions on how to screen, assessment tools
including NPI-Q, a Behavior Screen, Safety Assessment/Guide, Caregiver Profile/stress,
End-of Life Checklist here.
o General information here.



Institute a two-step process for diagnosis supported by a clear, clinical protocol. Support and
train providers and staff on the value of early detection, how to comfortably talk about
dementia, and on the uncertainty that can accompany the diagnosis. Refer to the Position Paper
from the Dementia Action Collaborative for guidance.
o First Step: Initial screening through the Medicare Annual Wellness visit (if Medicare) or
other visit (Medicaid, private insurance). Follow steps as outlined in the Alzheimer’s
Association Medicare Annual Wellness Visit Algorithm for Assessment of Cognition in
Appendix D. Use a brief (<5 minutes), validated tool or direct observation with
consideration of information obtained by family members, friends or others when
screening.
o Second Step: A positive finding results in a follow-up visit with additional evaluation and
confirmation of the diagnosis, if needed. This follow-up visit may use the CPT code
99483 (i.e., detailed structural assessment of dementia or Alzheimer’s disease
performed by a clinician that cannot be done the same day as an office visit).13
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Include family members or other caregivers as identified by the patient in the
conversation.
Have an empathetic, realistic, and patient- and family-centered (e.g., using
lower literacy materials if appropriate) advance care planning conversation
about wishes, goals, and values for end-of-life care. Include the caregivers and
especially the individual designated as the durable power of attorney for health
care in the conversation. Talk about the difference between an advance
directive and POLST and situations in which each would be acceptable.
Document:


An advance directive that stipulates specific treatment preferences (if
known and applicable to the situation),



A durable power of attorney for health care that names a surrogate and
indicates the amount of leeway the surrogate should have in decisionmaking, and



A written personal statement that articulates the patient’s values and
goals regarding end-of-life care.

 POLST, if appropriate.
Diagnostics should include:


Additional testing to validate diagnosis (see the Position Paper from the
Dementia Action Collaborative)



Assessment of other treatable causes of cognitive impairment including:
o Sleep apnea
o Alcohol use (e.g., using the Alcohol Use Disorders Identification
Test (AUDIT))
o Depression (e.g., using the Patient Health Questionnaire-9)
o Overview of other medications that might impact cognition
(e.g., benzodiazepines)



Laboratory testing to rule out treatable causes of cognitive impairment
including a complete metabolic panel and other tests as clinically
indicated.14



Additional dementia screening labs



Contingent labs (per patient history): RPR or MHA-TP, HIV, heavy metals



o

Imaging (e.g., CT, MRI) may be appropriate in certain situations as
clinically indicated.
 Assess activities of daily living and any patient, family, or other caregiver
concerns.
Assess risk and quality of life
 Inquire about driving status and safety (outlined here).
 Assess hearing loss if not already done.
 Inquire about home safety and assess for risk of falls
 Assess for depression and risk of suicide
 Discuss how to mitigate confusion, agitation, aggression, and/or wandering
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Assess for sleep quality and sleep disturbance
Review and manage medications
Caregiver stress, capacity, and support

After diagnosis, connect patient and family to appropriate local and/or state/national sources of
care and support:
o The county’s Area Agency on Aging provider (including referrals for family and caregiver
support such as respite care facilities)
o African American Elders Program
o Alzheimer’s Association of Washington State
o Alzheimer Society of Washington
o American Association of Retired Persons (AARP)
o American Automobile Association (AAA) Senior Drivers
o Chinese Information and Service Center
o Community Living Connections including resources by county
o Momentia Seattle
o National Institute on Aging
o Open Doors for Multicultural Families
o Seattle Indian Health Board
o Path with Art
Provide a copy of or other access to the Washington State Dementia Action Collaborative’s
Dementia Road Map: A Guide for Family and Care Partners

Ongoing Care and Support/Management


Incorporate the dementia diagnosis and consideration for the patient’s cognitive function into
shared decision making for routine medical care including into decisions about unnecessary or
potentially harmful care (e.g., mammograms).



Continue to include the patient and family or other caregivers as part of the care team.
o Look for signs of caregiver distress. Support caregivers and assess and note caregiver
knowledge, skills, capacity and possible distress at each visit. Connect caregivers with
available resources.



Identify the patient’s goals of care and work to maximize function that meet patient and family
needs at each stage of the disease.



Work with health care team to appropriately treat conditions that can worsen symptoms or lead
to poor outcomes, including depression and existing medical issues.



Routinely assess complexities of managing patients with dementia and the needs of family care
partners for enhanced support.



Offer evidence-based dementia care management services (including home health, phonesupport and enhanced outpatient management) to patients and caregivers who have been
determined to be high-risk. This high-risk group may include patients that have several medical
comorbidities, complex medication regiments, behavioral/psychiatric symptoms, and/or history
of frequent utilization of acute care services.
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Offer appropriate interventions. Level of support offered depends on patient-specific factors
including complexity and severity of disease, comorbid health conditions, level of caregiver
support, and other factors.
o Educate family about the diagnosis and available treatment including the natural
progression of dementia.
 Talk about the benefit of cardiovascular exercise
 Talk about the benefits of mindful changes to diet (e.g., increasing daily fruit and
vegetable intake)
o Discuss neuropsychiatric symptoms (e.g., agitation, psychosis) and management
strategies using a shared-decision making approach appropriate to the patient. Manage
with non-pharmacologic treatments first, consulting with behavioral health providers
when possible.
o Continue to offer information about available community supports.

Planning for Higher Care Needs and Hospitalizations



Discuss possible red flags that may necessitate admission to an acute care setting as well as risks
and benefits of hospitalization.
Discuss how to plan and prepare for a potential inpatient stay including risks and benefits of a
hospitalization and when the patient may want to be hospitalized and when they may not want
care in a hospital setting.



Monitoring for and communicate to the patient and family members about:
o Progression of cognitive decline
o Emergence of behavioral symptoms
o Functional impairment (e.g., activities of daily living)
o Care-partner/family capacity



Talk with patients and family about the potential need for receiving additional in-home supports
or transitioning to a higher level of care (e.g., residential care facility) if care needs are greater
than can be safely managed. Planning should include consideration for caregiver capacity,
financial and insurance concerns (e.g., long term care coverage), health care considerations, and
availability of local residential facilities, paid caregivers, and community resources (e.g., Meals
on Wheels, volunteer chore services).



Be aware that delirium may be an issue after surgery. Talk about this risk with patients and
family members.

Advance Care Planning and Palliative Care


If not already done as part of the diagnostic process or completed earlier, have an empathetic,
realistic, and patient- and family-centered (e.g., using lower literacy materials if appropriate)
advance care planning conversation about wishes, goals, and values for end-of-life care. Include
the caregivers and especially the individual designated as the durable power of attorney for
health care in the conversation. Talk about the difference between an advance directive and
POLST and situations in which each would be acceptable. Document:
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o
o
o
o

An advance directive that stipulates specific treatment preferences (if known and
applicable to the situation),
A durable power of attorney for health care that names a surrogate and indicates the
amount of leeway the surrogate should have in decision-making, and
A written personal statement that articulates the patient’s values and goals regarding
end-of-life care.
POLST, if appropriate.



Discuss palliative care with the patient and family or other caregivers as well as whether or not
hospice care might be appropriate.



Ensure that the patient and family know who to contact if symptoms (e.g., pain) develop or
worsen. Ask if the patient and family feel confident in their care plan and work to fill any gaps.

Residential Facilities


Provide regular dementia-specific training for staff, including environmental and nonpharmacological interventions for neuropsychiatric symptoms.



Educate health care providers and staff on:
o Symptoms of hearing loss and how to communicate with persons who have hearing loss.
Information on how to communicate with someone who has hearing loss here.
o How to have empathetic, realistic, and patient- and family-centered (e.g., using lower
literacy materials if appropriate) advance care planning conversations. The difference
between an advance directive and POLST, and patients for whom each would be
acceptable.
o How to refer patients to community-based advance care planning resources if
appropriate.
o Explaining the terms on an advance directive and POLST to family and friends at the end
of a patient’s life
o Supporting the patient, family, and friends during a time of crisis.



Work to promote discussions with residents about how to have conversations regarding
personal goals of care and the type of care desired at the end of life with family members,
friends, and health care providers; the importance of having an advance directive that includes a
living will (also known as a health care directive), a durable power of attorney for health care,
and a written personal statement about health care goals and values; and the difference
between POLST and an advance directive.



Enter advance directives and/or POLST into the patient’s medical record once completed and
communicate with the patient and his or her primary care provider as to whether the patient
has advance directives and/or a POLST in his or her medical record.



Promote awareness of the value of palliative care and hospice and encourage appropriate
hospice referrals.



Implement a quality improvement program to encourage greater adherence to patients’
requests as outlined in advance directives and POLST if accurate and applicable to the current
situation.
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Measure family satisfaction with end-of-life care by widespread use of an after-death survey
tool similar to that used by hospice agencies.



Support patients as they navigate care between different health care facilities and systems
including facilitation of information sharing and patient and family outreach during times of
crisis.

Hospitals


Educate staff about Alzheimer’s disease and other dementias including on disease progression,
care needs, communication, involving the family and other caregivers in decisions, and potential
impact on hospitalization.



Screen all at-risk (e.g., ≥ 65 years old) patients on admission for risk of delirium using a brief
cognitive test (e.g., Confusion Assessment Method or CAM)
o If delirium is detected, provide targeted, multimodal prevention strategies aligned with
the NICE clinical guidelines. This should include the use of bedside tests daily in the first
days after surgery (e.g., Confusion Assessment Method-Intensive Care Unit or CAM-ICU,
Delirium Detection Score).
o Incorporate results into the medical record and confirm care team is aware of results.
o Talk to the patient and family about the risk for delirium after surgery, what symptoms
might look and feel like, management strategies, and what delirium might mean for
recovery.



Be sure that all treating clinicians and other staff are aware of a patient’s dementia diagnosis
and hearing loss and understand the patient’s communication ability, behavioral concerns (e.g.,
agitation, exit seeking, wandering), and other information that the patient may not be able to
communicate (e.g., allergies, other reactions to medications, dietary preference).



Discharge
o Support the patient and family members whether the patient is being discharged to a
home or to a residential care or rehabilitation facility.
o Assess family and caregiver support and feasibility of providing care at home (e.g.,
activities of daily living) including connecting to any available community supports (e.g.,
in-home services). Local and/or state/national sources of care and support may include:
 The county’s Area Agency on Aging provider (including respite care referrals)
 Alzheimer’s Association of Washington State
 Alzheimer Society of Washington
 American Association of Retired Persons (AARP)
 American Automobile Association (AAA) Senior Drivers
 Momentia Seattle
 National Institute on Aging
o If the patient is being discharged to a residential facility, identify facilities with vacancies
and help the patient and family make a decision (e.g., meetings their needs, is certified
by Medicare, is reasonable distance, has training or services specific to patients with
cognitive impairment).
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o
o


Discuss factors like length of stay, cost, services to be conducted, and other patient
questions.
The hospital team communicates with the facility or caregiver discharge instructions,
current medications, and follow-up appointment needs.

Educate health care providers and staff on:
o How to have empathetic, realistic, and patient- and family-centered (e.g., using lower
literacy materials if appropriate) advance care planning conversations
o How to be reimbursed for these conversations.
o The difference between an advance directive and POLST, and patients for whom each
would be acceptable.
o How to refer patients to community-based advance care planning resources if
appropriate.
o
o

Explaining the terms on an advance directive and POLST to family and friends at the end
of a patient’s life
Supporting the patient, family, and friends during a time of crisis.



Review your facility’s protocols around asking about and honoring advance directives to
decrease barriers to patients’ wishes being honored at the end of life.



Enter advance directives and/or POLST into the patient’s medical record once completed and
communicate with the patient and his or her primary care provider as to whether the patient
has advance directives and/or a POLST in his or her medical record.



Promote awareness of the value of palliative care, hospice, encourage appropriate hospice
referrals, and be sure to communicate any referrals back to the patient’s primary care provider.



Support patients as they navigate care between different health care facilities and systems
including facilitation of information sharing and patient and family outreach during times of
crisis.

Health Plans


Increase member awareness of how to maintain overall heart and brain health with age, about
the difference between age-related changes in memory and the warning signs of dementia, and
about the benefits of timely diagnosis of Alzheimer’s disease and other dementias.



Encourage hospitals, nursing homes, and other applicable settings to implement a quality
improvement program focused on greater adherence to patients’ requests as outlined in
advance directives and POLST if accurate and applicable to the current situation



Measure patient and family satisfaction with dementia care with use of a survey tool similar to
that used by hospice agencies.



Develop inclusive and comprehensive benefits for patients with Alzheimer’s disease or other
dementia allowing them to receive care consistent with their wishes and goals even if not
eligible for hospice (e.g., palliative care).



Support patients as they navigate care between separate health care facilities and systems
including facilitation of information sharing and patient and family outreach during crisis.
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Employers


Recognize that many employees may be serving as informal caregivers to their family members
or others. Incorporate caregiver supports into employee assistance programs.



Educate your employees about how to have conversations regarding personal goals of care and
the type of care desired at the end of life with family members, friend, and health care
providers; the importance of having an advance directive that includes a living will (also known
as a health care directive), a durable power of attorney for health care, and a written personal
statement about health care goals and values; and the difference between POLST and an
advance directive.



Promote employee wellness by increasing awareness of how to maintain overall heart and brain
health with age, about the difference between age-related changes in memory and the warning
signs of dementia, and about the benefits of timely diagnosis of Alzheimer’s disease and other
dementias.

Washington State Health Care Authority


Promote awareness and utilization of advance care planning at multiple levels of health care
delivery systems.
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Diagnosis
The workgroup recommends early detection of mild cognitive impairment (MCI) in order to better
support the patient and family members but does not recommend population-level screening of older
adults. Early detection supports patients and family members and allows patients and families to plan
for future cognitive changes. The Dementia Action Collaborative has developed a clinical protocol for
diagnosis, available here.
The United States Preventive Services Task Force is currently updating their recommendation on
screening for cognitive impairment in older adults. A previous review in 2013 found insufficient evidence
to either recommend for or against population-level screening.15 While current data may be lacking to
support comprehensive population-level screening, the workgroup’s expert opinion agrees with the
potential benefits of early detection and supports efforts in this area.
The Patient Protection and Affordable Care Act added an annual wellness visit as a new Medicare
benefit in January 2011 requiring a health risk assessment and assessment of cognitive impairment (no
specific tool is endorsed).16 The Alzheimer’s Association convened a workgroup to guide adoption of this
inclusion, reviewing available evidence on validated tools to assess cognitive impairmenti and
recommends using either the General Practitioner Assessment of Cognition (GPCOG), the Mini-Cog
(repeating three unrelated words, performing clock drawing test, repeating the three unrelated words),
or the Memory Impairment Screen (MIS) due to each being less than five minutes to administer,
validated, easily administered by non-clinical
Addressing Barriers
staff, and free from bias and need for
The workgroup understands that time is one of the
payment for copyright.17,18,19 Our Report and
most significant barriers to addressing patient and
Recommendations does not review the
family concern about memory loss and a diagnosis.
specificity and sensitivity of the various
CPT code 99483 was developed to reimburse
separately for assessment and care plan development
screening tests as that has been done
for Medicare beneficiaries with cognitive impairment.
elsewhere. The Alzheimer’s Association
Find more information on background,
developed a Medicare Annual Wellness Visit
implementation, and use from the Alzheimer’s
Algorithm for Assessment of Cognition,
Association through the following links:
included in Appendix D. The workgroup
 www.alz.org/careplanning/downloads/cmsendorses this algorithm as a best-practice
consensus.pdf
clinical pathway and recommends this as the
 http://alz.org/careplanning/downloads/carefirst step of a two-step process followed by
planning-toolkit.pdf
further evaluation or formal cognitive testing
 www.alz.org/careplanning/
with a longer instrument. Further evaluation
can often be out of the scope of the annual
wellness visit and can be done on the same day or as a new visit that may include family members or
caregivers not present at the annual wellness visit. This two-step process is supported by the
Alzheimer’s Association and is recommended due to being time-efficient.20 This second diagnostic step
i

The Alzheimer’s Association reviewed: 7-Minute Screen, Abbreviated Mental Test, Blessed Orientation-Memory-Concentration
Test (long and short), Cambridge Cognitive Examination, Clock Drawing Test, General Practitioner Assessment of Cognition,
Mini-Cog, Memory Impairment Screen, Mini-Mental State Examination, Montreal Cognitive Assessment, Rowland Universal
Dementia Assessment, Sweet Screening Instrument, The Short Portable Mental Status Questionnaire, Short Test of Mental
Status, Time and Change Test
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can be done by the primary care provider or through a referral within or outside of the practice (e.g., to
a neurologist, neuropsychologist). Caregiver(s) or other family members should be present for this visit.

Ongoing Care and Support/Management
Patient self efficacy is important for positive patient outcomes. The workgroup recommends working to
instill hope in those diagnosed with dementia and their family members and other caretakers. Many
diseases (e.g., pain, hypertension) have been shown to have increased positive outcomes with a positive
patient mindset, including Alzheimer’s disease.21 The 2017 Lancet International Commission on
Dementia, Prevention, Intervention, and Care focuses on nine modifiable risk factors (that contribute to
about 35% of dementia cases) based on patient age: (1) early life: education to at least age 15; (2) midlife: reducing hypertension, obesity, and hearing loss; and (3) later life: reducing depression, managing
diabetes, increasing physical activity, smoking cession, and increasing social contact.22 Intervening in
these areas has been called a priority for public health.23 The link between cerebrovascular disease and
dementia risk is well established, and should be part of conversations about prevention.24 The Lancet
Commission also recommends individualized dementia care, supporting caregivers, end-of-life care
planning, and planning for future care needs, among others.25
Interventions
Pharmacologic treatment approved for Alzheimer’s disease and recommended by the American
Academy of Neurology, The American College of Physicians, the American Academy of Family Physicians,
the American Psychiatric Association, and the American Geriatric Society include cholinesterase
inhibitors or memantine for patients diagnosed with Alzheimer’s disease after a discussion with the
patient about risks and benefits.26,27 While clinical research into experimental drugs targeting the
proteins associated with cognitive decline have recently not met with success, the most promising
interventions include exercise and diet modification.28
The Agency for Healthcare Research and Quality conducted a systematic review of interventions to
prevent age-related cognitive decline, cognitive impairment, and clinical Alzheimer’s type-dementia,
completed March 2017.29 Interventions under review included “cognitive training, physical activity,
nutraceuticals, diet, multimodal interventions, hormone therapy, vitamins, antihypertensive treatment,
lipid lowering treatment, nonsteroidal anti-inflammatory drugs (NSAIDs), antidementia drugs, diabetes
treatment, and other.” Analysis found no high-strength evidence to delay or prevent cognitive decline,
medium strength evidence that cognitive training has positive effects on adults with presumed normal
cognition, and weak evidence for cognitive training on adults with clinical Alzheimer’s disease or other
dementias. Other interventions such as vitamins (e.g., vitamin E in women, B12 plus folic acid) were
associated with positive outcomes (weak evidence) with a general trend toward efficacy for physical
activity and vitamin B12 plus folic acid.
Other systematic reviews have focused on specific interventions and found more promising results.
Exercise has been shown to be associated with a reduction in the risk of diagnosis with Alzheimer’s
disease and in some studies to be associated with improved cognition and balance after diagnosis.30,31
Specific diets high in vitamin E, B vitamins, and the n-3 fatty acid and low in saturated fat have also been
associated with slowed cognitive decline.32 The Mediterranean–DASH Intervention for
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Neurodegenerative Delay, based on the Dietary Approaches to Stop Hypertension diet, has been shown
to be associated with slower rates of cognitive decline and lower incidence of Alzheimer’s disease.33,34,35
Other multimodal interventions, including the Finnish Geriatric Intervention Study to Prevent Cognitive
Impairment and Disability (FINGER) study that include a combination of nutritional guidance, exercise,
cognitive training, social activity, and management of metabolic and vascular risk factors have been
shown to be associated with a reduction in cognitive decline or maintenance of function.36 These
multimodal interventions are more difficult to adopt in the United States health care environment, but
elements may be suited for widespread use.
Communication and shared-decision making, advance care planning and care goals, and keeping the
patient at the center of care have been identified by other researchers as key goals for palliative care for
patients with dementia.37 However, inclusion of palliative care into guidelines for patients with
dementia has significant gaps, with less attention to end of life care than to other areas, especially
around grief.38

Palliative Care and End of Life Care
This workgroup draws on the Bree Collaborative’s previous work around end-of-life care. The Bree
Collaborative convened a workgroup that met from January to November 2014. The workgroup’s goal is
that all Washingtonians be informed about their end-of-life options, communicate their preferences in
actionable terms, and receive end-of-life care that is aligned with their wishes, goals, and values. The
workgroup to developed the following five focus areas corresponding to how an individual would ideally
experience advance care planning for the end of life. These focus areas work to empower patients to
voice their wishes and make sure that the care that all Washingtonians receive at the end of life is the
care that they and their families want. The recommendations are highly aligned with this workgroup.
Read the Report here and see focus areas below:
1.
2.
3.

4.
5.

Increase awareness of advance care planning, advance directives, and Physician Orders for Life Sustaining
Treatment (POLST) in Washington State
Increase the number of people who participate in advance care planning in the clinical and community
settings
Increase the number of people who record their wishes and goals for end-of-life care using documents
that: accurately represent their values; are easily understandable by all readers including family members,
friends, and health care providers; and can be acted upon in the health care setting
Increase the accessibility of completed advance directives and POLST for health systems and providers
Increase the likelihood that a patient’s end-of-life care choices are honored

Transitions of Care
The workgroup framed transitions of care from a patient perspective, acknowledging that patients and
family members will need to both think about (1) increasing needs for care and support at home, (2)
transitions from the home into higher levels of care, and (3) that hospitalization may occur and the
patient may then need to transition from the hospital to either the home or to a residential care facility.
Care transitions can be stressful for the patient and family, and if not well managed can result in patient
safety issues and poor care outcomes.39 Health professionals report need for discharge planning for
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patients with dementia to routinely exceed supply with critical issues around communication with other
care settings and around medication.40 Patients admitted to the inpatient setting are often not assessed
for dementia and staff can be untrained on how to safely manage patients with dementia.41 Guidelines
for patients stress the importance of pre-planning for a potential hospital admission and for protocols
that support patient assessment of dementia and planned next steps to mitigate behavioral concerns
and patient safety issues (e.g., wandering).42

Delirium
Delirium is an acute change in cognition and attention defined in the DSM-V as “Disturbance in attention
(i.e., reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to
the environment) [that] develops over a short period of time (usually hours to a few days), represents an
acute change from baseline attention and awareness, and tends to fluctuate in severity during the
course of a day.”43 Delirium is not due to a preexisting condition, but cognitive impairment is a risk
factor as is depression and functional status, and can cause poor health outcomes, stress for family
members and other caregivers, and can be underdiagnosed. 44 Delirium has been associated with an
increased risk of death and risk of institutionalization, independent of baseline dementia.45 As many as
52% (range 37-52%) of elderly patients undergoing cardiac surgery and 65% (25-65%) undergoing hip
replacement have experienced delirium.46
The National Institute for Health and Clinical Excellence (NICE) developed a Guideline for Prevention of
Delirium including 13 clinical recommendations for hospitalized patients and for at-risk adults in longterm care settings, listed in Appendix F.47 The workgroup endorses these clinical recommendations and
recommends that at-risk patients be screened for delirium using a brief cognitive test (e.g., CAM) to
allow for risk assessment of post-operative delirium and as a comparison to post-surgical testing. If
delirium is detected, the workgroup recommends targeted, multimodal prevention strategies aligned
with the NICE clinical guidelines. This should include the use of bedside tests daily in the first days after
surgery (e.g., Confusion Assessment Method-Intensive Care Unit (CAM-ICU), Delirium Detection
Score).48 Family and other caregivers should be provided with education and appropriate coping skills to
recognize and manage delirium.49
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Other Work in Washington State
Developing a Washington State Plan
Governor Jay Inslee convened a Washington State Aging Summit in 2013 with leaders from public and
private sectors around the need for a Washington State-specific Alzheimer’s disease state plan. The
Legislature answered this charge in 2014 with Senate Bill 6124 that created a taskforce, the Alzheimer’s
Disease Working Group, to look at the needs of those with Alzheimer’s disease and other dementias,
services within Washington State to meet needs, and projecting future population-level needs and
system capacity.50 The Working Group released the Alzheimer’s State Plan in January 2016 including:


Goals – Broad visionary statements



Strategies – High-level plans to achieve the goals



Recommendations – Specific responses or actions
Read the Washington State Plan to Address Alzheimer’s Disease and Other Dementias

Like the State Plan, this Report and Recommendations is based on a public-private framework, builds on
previous work that is person and family-centered, and that takes a life-course approach. The
Washington State Plan contains much more comprehensive epidemiological information than this
Report and Recommendations. We encourage those interested in further information to consult the
State Plan.
The Dementia Action Collaborative (DAC) formed in April 2016 to implement the State Plan through a
focus on: (1) public awareness and community readiness, (2) long-term services and supports, and (3)
health and medical best practices. A public-private partnership made up of 37 stakeholders representing
those with dementia, family caregivers, medical providers, researchers, Legislators, Washington State
Agency staff, and support organizations, the DAC prioritized recommendations that could be
accomplished through heightened collaboration and within existing state resources, that could sustain
momentum and awareness through partnerships. The Bree Collaborative was engaged as a partner in
July of 2016 and selected Alzheimer’s disease and Other Dementias as a topic around which to develop
clinical recommendations. This builds from the health and medical subcommittee action item to
convene an expert panel to identify and endorse evidence-based standards for diagnosis, treatment,
supportive care, and advanced planning.
Learn more about the Dementia Action Collaborative.
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Measurement
We encourage organizations to operationalize metrics as relevant to their organization. Healthy People
2020 includes two Alzheimer’s disease and other dementias related metrics:



Diagnosis awareness among persons with Alzheimer's disease and other dementias or their
caregiver (percent, 65+ years)
Preventable hospitalizations among persons with Alzheimer's disease and other dementias
(percent, 65+ years)

The American Academy of Neurology proposes has proposed nine metrics to measure quality of care for
those with Alzheimer’s disease and other dementias.51 Many of these measures are aligned with the
focus areas of this set of recommendations.
Table 2: American Academy of Neurology Proposed Metrics for Those with Alzheimer’s Disease and
Other Dementias
Title
1. Disclosure of dementia
diagnosis
2. Education and support of
caregivers for patients
with dementia
3. Functional status
assessment for patients
with dementia
4. Screening and
management of
behavioral and psychiatric
symptoms associated
with dementia (BPSD)
5. Safety concern screening
and follow-up for patients
with dementia

6. Driving screening and
follow-up for patients
with dementia
7. Advance care planning
and palliative care
counseling for patients
with dementia

8. Pain assessment and
follow-up for patients
with dementia
9. Pharmacologic treatment
of dementia

Description
Percentage of patients with a diagnosis of a qualifying dementing disorder or
disease whose diagnosis has been disclosed to them and, if available, their primary
caregiver
Percentage of patients with dementia whose caregivers were provided with
education on dementia disease management and health behavior changes and
were referred to additional resources for support in the last 12 months
Percentage of patients with dementia for whom an assessment of functional status
was performed at least once in the last 12 months
Percentage of patients with dementia for whom there was a documented
screening for behavioral and psychiatric symptoms, including depression, and for
whom, if screening positive, there was also documentation of recommendations
for management in the last 12 months
Percentage of patients with dementia or their caregivers for whom there was a
documented safety screening in 2 domains of risk, dangerousness to self or others
and environmental risks, and for whom, if screening positive, there was
documentation they were provided with recommendations for their mitigation,
which may include referral to other resources, in the last 12 months
Percentage of patients with dementia for whom there was a documented
screening for driving risks and for whom, if screening positive, there was also
documentation they were informed of alternatives to driving in the last 12 months
Percentage of patients with dementia who have an advance care plan or surrogate
decision-maker documented in the medical record or documentation in the
medical record that an advance care plan was discussed but the patient did not
wish or was not able to name a surrogate decision-maker or provide an advance
care plan and percentage of patients with dementia or their surrogate decisionmaker who received comprehensive counseling regarding ongoing palliation and
symptom management and end-of-life decisions within 2 years of initial diagnosis
or assumption of care
Percentage of patients with dementia who underwent documented screening for
pain symptoms at every visit and if screening positive also had a documentation of
a follow-up plan
Percentage of patients with dementia or their caregivers with whom available
guideline-appropriate pharmacologic treatment options and nonpharmacological
behavior and lifestyle modifications were discussed at least once in the last 12month period

Sanders A, Nininger J, Absher J, Bennett A, Shugarman S, Roca R. Quality improvement in neurology: Dementia management
quality measurement set update. Neurology. 2017 May 16;88(20):1951-1957.
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Appendix A: Bree Collaborative Members
Member
Susie Dade MS
John Espinola MD, MPH
Gary Franklin MD, MPH

Title
Deputy Director
Executive Vice President,
Health Care Services
Medical Director

Stuart Freed MD
Richard Goss MD

Chief Medical Officer
Medical Director

Jennifer Graves, RN, MS

Senior Vice President, Patient
Safety
President, MultiCare
Connected Care
Chief Medical Officer

Christopher Kodama MD
Daniel Lessler MD, MHA
Paula Lozano MD, MPH

Carl Olden MD

Associate Medical Director,
Research and Translation
Chief Medical
Officer, Accountable Care
Organization
Director, Benefits & Policy
and Strategy
Medical Director, Center for
Health Care Solutions
Associate Chief Medical
Officer
Family Physician

Mary Kay O’Neill MD, MBA
John Robinson MD, SM
Terry Rogers MD (Vice Chair)

Partner
Chief Medical Officer
Chief Executive Officer

Jeanne Rupert DO, PhD

Hugh Straley MD (Chair)

Medical Director, Community
Health Services
Strategic Planner for
Employee Health
Medical Director
Vice President, Health Care
Management Services
Retired

Shawn West MD

Family Physician

Wm. Richard Ludwig MD

Greg Marchand
Robert Mecklenburg MD
Kimberly Moore MD

Kerry Schaefer
Bruce Smith MD
Lani Spencer RN, MHA
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Organization
Washington Health Alliance
Premera Blue Cross
Washington State Department
of Labor and Industries
Confluence Health
Harborview Medical Center –
University of Washington
Washington State Hospital
Association
MultiCare Health System
Washington State Health Care
Authority
Kaiser Permanente
Providence Health and Services

The Boeing Company
Virginia Mason Medical Center
Franciscan Health System
Pacific Crest Family Medicine,
Yakima
Mercer
First Choice Health
Foundation for Health Care
Quality
Public Health – Seattle and King
County
King County
Regence Blue Shield
Amerigroup
Medical Director, Group Health
Cooperative; President, Group
Health Physicians
Edmonds Family Medicine
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Appendix B: Alzheimer’s Disease and Other Dementias Workgroup Charter and Roster
Problem Statement
Washington State has the third highest rate of death from Alzheimer’s disease of any state.1iiThis is
expected to increase 40% in next 10 years and 181% over the next 30 years.1 In many practices in
Washington State, there are no guidelines to increase quality of care for screening, diagnosis, or
treatment of Alzheimer’s disease and other dementias.2iiiThis is costly to the health care system and
overly burdensome to primary care clinicians, and patients, their caregivers, and the community.
Aim
To align care delivery with existing evidence-based standard of care for diagnosis, treatment, supportive
care, and advanced care planning within primary care for patients with Alzheimer’s disease or other
dementias and their families and caregivers while decreasing variation in quality of treatment across the
state of Washington.
Purpose
To propose evidence-based recommendations to the full Bree Collaborative on:


Aligning with the Alzheimer’s State Plan and the Alzheimer’s Disease Working Group.



Diagnostic tools for Alzheimer’s disease and other dementias.



Offering supportive care to patients and their family and other caregivers including medication
management and managing co-morbid conditions.



Support with late-stage dementia and advance care planning.



Referring to other resources such as counseling, senior day programs, or palliative care of those
with dementia.



Identifying other areas of focus.

Duties & Functions
The Alzheimer’s Disease and Other Dementias workgroup will:


Research evidence-based guidelines and best practices (emerging and established).



Consult relevant professional associations and other stakeholder organizations and subject
matter experts for feedback, as appropriate.



Meet for approximately nine months, as needed.



Provide updates at Bree Collaborative meetings.



Post draft report(s) on the Bree Collaborative website for public comment prior to sending report
to the Bree Collaborative for approval and adoption.



Present findings and recommendations in a report.



Recommend data-driven and practical implementation strategies.



Create and oversee subsequent subgroups to help carry out the work, as needed.

1iiAlzheimer’s Association. Alzheimer’s Statistics Washington. Available:
www.alz.org/documents_custom/facts_2016/statesheet_washington.pdf
2iiiWashington State Department of Social and Health Services. Washington State Plan to Address Alzheimer’s Disease and Other Dementias.
January 1, 2016. Available:
www.dshs.wa.gov/sites/default/files/SESA/legislative/documents/2016%20WA%20Alzheimer%27s%20State%20Plan%20%20Full%20Report%20Final.pdf
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Revise this charter as necessary based on scope of work.

Structure
The workgroup will consist of individuals confirmed by Bree Collaborative members or appointed by the
chair of the Bree Collaborative or the workgroup chair.
The chair of the workgroup will be appointed by the chair of the Bree Collaborative.
The Bree Collaborative program director will staff and provide management and support services for the
workgroup.
Less than the full workgroup may convene to: gather and discuss information; conduct research; analyze
relevant issues and facts; or draft recommendations for the deliberation of the full workgroup. A quorum
shall be a simple majority and shall be required to accept and approve recommendations to send to the
Bree Collaborative.
Meetings
The workgroup will hold meetings as necessary. The program director will conduct meetings along with
the chair, arrange for the recording of each meeting, and distribute meeting agendas and other materials
prior to each meeting. Additional workgroup members to be added at the discretion of the chair.
Name
Kristoffer Rhoads, PhD
(Chair)
Kimiko Domoto-Reilly, MD

Title
Primary Neuropsychologist,
Memory and Brain Wellness
Center
Alzheimer's Research Center

Richard Furlong, MD
Barak Gaster, MD

Primary Care
Professor of Medicine

Kelly Green, MSW
Debbie Hunter
Nancy Isenberg, MD, MPH,
FAAN

Todd Larson
Myriam Marquez
Shirley Newell, MD
Darrell Owens, DNP, ARNP

Social Worker
Family Caregiver
Neurologist, Clinical Associate
Professor of Neurology, Center
for Healthy Aging & Memory
Family Caregiver
Primary Care
Vice President for Research and
Health Care Innovation
Family Caregiver
Patient Advocate
Chief Medical Officer
Clinic Chief, Director

Tatiana Sadak, PhD, ARNP

Psychiatric Nurse Practitioner

Bruce Smith, MD

Medical Director

Arlene Johnson
Kerry Jurges, MD
Eric Larson, MD, MPH
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Organization
University of Washington Medical
Center
University of Washington Medical
Center
Virginia Mason Medical Center
University of Washington Medical
Center
Evergreen Health
Virginia Mason Medical Center

Confluence Health
Kaiser Foundation Health Plan of
Washington

Aegis Living
University of Washington
Outpatient Primary, Palliative and
Supportive Care Program
Associate Professor of Geriatric
Mental Health, University of
Washington School of Nursing
Regence Blue Shield
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Appendix C: Guideline and Systematic Review Search Results
Source
AHRQ: Research
Findings and
Reports
Cochrane
Collection

Guidelines or Systematic Reviews
(2017) Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive
Impairment, and Clinical Alzheimer’s-Type Dementia
(2016) Non-pharmacologic Interventions for Agitation and Aggression in
Dementia
(2017) The use of vitamin E in the treatment of mild cognitive impairment and
Alzheimer's disease (AD)
(2017) Proteins in cerebrospinal fluids (CSF) for early prediction of developing
Alzheimer’s disease or other dementia in people with mild cognitive problems
(2017) Is dance movement therapy an effective intervention for dementia? A
review of the evidence
(2016) Medicines for sleep problems in dementia
(2016) Treatment of epilepsy for people with Alzheimer's disease
(2016) Statin withdrawal in people with dementia
(2016) Omega-3 fatty acids for the treatment of dementia
(2016) Mini-Mental State Examination (MMSE) for the detection of dementia in
people aged over 65
(2016) Statins for the prevention of dementia
(2015) Montreal Cognitive Assessment (MoCA) for the diagnosis of Alzheimer's
disease and other dementias
(2015) Rivastigmine for people with Alzheimer's disease
(2015) Regional Cerebral Blood Flow SPECT for detection of Frontotemporal
dementia in people with suspected dementia
(2015) Dimebon for Alzheimer's disease
(2015) Baseline scores of Mini-Mental State examination (MMSE) for early
prediction of developing dementia in people with mild cognitive impairments
(MCI)
(2015) Cholinesterase inhibitors for rarer dementia associated with neurological
conditions
(2015) A brief cogntive screening test (Mini-Cog) for the assessment of possible
dementia
(2015) Dopamine transporter imaging for the diagnosis of dementia with Lewy
bodies
(2015) ¹⁸F-FDG PET scan for early prediction of developing Alzheimer’s disease or
other dementia in people with mild cognitive impairment (MCI)
(2014) 11C-PIB-PET scan for early prediction of developing Alzheimer’s disease or
other dementia in people with mild cognitive impairment (MCI)
(2014) Statins for the treatment of Alzheimer's disease
(2014) Proteins in blood and cerebrospinal fluids for early prediction of
developing Alzheimer’s disease or other dementia in people with cognitive
problems
(2014) There is no evidence that MPACs (PBT1 or PBT2) are of benefit in
Alzheimer's dementia
(2014) Management of faecal incontinence and constipation in adults with central
nervous system diseases
(2013) Cognitive training and cognitive rehabilitation for mild to moderate
Alzheimer's disease and vascular dementia
(2013) Rivastigmine for vascular cognitive impairment
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Specialty Society
Guidelines
(via Guideline
Clearinghouse
including
Choosing Wisely)

Health
Technology
Assessment
Program

Center for
Disease Control
and Prevention
National Institute
on Aging

(2013) Withdrawal of chronic antipsychotic drugs for behavioural and
psychological symptoms in older people with dementia
(2013) Cerebrolysin for vascular dementia
(2012) No evidence from randomised controlled trials for or against the use of
huperzine A in the treatment of people with mild cognitive impairment
(2012) Anti-dementia drugs for people with memory problems but without
dementia
(2016) The American Psychiatric Association practice guideline on the use of
antipsychotics to treat agitation or psychosis in patients with dementia.
(2016) Canadian Task Force on Preventive Health Care Recommendations on
screening for cognitive impairment in older adults.
(2015) American Geriatrics Society American Geriatrics Society 2015 updated
Beers Criteria for potentially inappropriate medication use in older adults.
(2014 revised) American College of Radiology ACR Appropriateness Criteria®
dementia and movement disorders.
(2014 revised) U.S. Preventive Services Task Force Final Recommendation
Statement Cognitive Impairment in Older Adults: Screening
(2014) American Occupational Therapy Association, Inc. Occupational therapy
practice guidelines for home modifications.
(2013 revised) University of Iowa College of Nursing, John A. Hartford Foundation
Center of Geriatric Nursing Excellence Bathing persons with dementia.
(2013) Alzheimer's Association, Society of Nuclear Medicine and Molecular
Imaging Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging
Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the
Alzheimer's Association.
(2013) Alzheimer's Association Alzheimer's Association recommendations for
operationalizing the detection of cognitive impairment during the Medicare
Annual Wellness Visit in a primary care setting.
(2012 revised) Hartford Institute for Geriatric Nursing Recognition and
management of dementia.
(2012 revised) American Medical Directors Association Dementia in the long term
care setting.
(2012 revised) Hartford Institute for Geriatric Nursing Assessing cognitive
functioning. In: Evidence-based geriatric nursing protocols for best practice.
(2012 revised) Hartford Institute for Geriatric Nursing Assessment and
management of mealtime difficulties.
(2012) Hartford Institute for Geriatric Nursing Managing oral hydration.
(2014) Functional neuroimaging for primary degenerative dementia or mild
cognitive impairment “Functional neuroimaging for primary degenerative
dementia or mild cognitive impairment is not covered. Functional imaging
technologies including: fludeoxyglucose (FDG) Positron Emission Tomography
(PET), (11)C-dihydrotetrabenazine (C-DTBZ) PET, Single Photon Emission
Computed Tomography (SPECT), Functional Magnetic Resonance Imaging (fMRI)
for the diagnosis of primary degenerative dementia or mild cognitive
impairment.”
Information: What is Alzheimer’s Disease?
Information: Healthy Brain Initiative
Information: Alzheimer's Disease & Related Dementias
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Institute for
Clinical and
Economic Review
BMJ Clinical
Evidence
Systematic
Overview
Veterans
Administration
Evidence-based
Synthesis
Program

No relevant reviews.

(2012) Dementia
(2007) Depression in adults: psychological treatments and care pathways

(2011) A Systematic Evidence Review of Non-pharmacological Interventions for
Behavioral Symptoms of Dementia
(2010) A Systematic Evidence Review of Interventions for Non-professional
Caregivers of Individuals with Dementia
(2010) A Systematic Evidence Review of the Signs and Symptoms of Dementia and
Brief Cognitive Tests Available in VA
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Appendix D: Alzheimer’s Association Medicare Annual Wellness Visit Algorithm for
Assessment of Cognition
Source: Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, et al. Alzheimer’s
Association recommendations for operationalizing the detection of cognitive impairment during the
Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 2013 Mar;9(2):141-50.
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Appendix E: Alzheimer’s Association Principles for a Dignified Diagnosis
Source: Alzheimer’s Association. Principles for a Dignified Diagnosis. Available:
www.alz.org/national/documents/brochure_dignified_diagnosis.pdf
Talk to me, the person living with dementia, directly. I am the person living with the disease, and
though those close to me will also be affected, I am the person who needs to know first.
Tell the truth. Even if you don’t have all of the answers, be honest about what you do know and why
you believe it to be so.
Test early. Helping me get an accurate diagnosis as soon as possible gives me more time to cope, live to
my fullest potential and access information and resources.
Take my memory concerns seriously, regardless of my age. Age may be the biggest risk factor for
Alzheimer’s, but Alzheimer’s is not a normal part of aging. Don’t discount my concerns because of my
age. At the same time, don’t forget that the disease can also affect people in their 40s, 50s and 60s.
Deliver the diagnosis in plain but sensitive language. My diagnosis may be one of the most important
things I ever hear. Please use language that I can understand and be sensitive to how this may make me
feel.
Coordinate with other care providers. I may be seeing more than one doctor. It’s important that you
talk to my other care providers to ensure everyone has the information so that changes can be
identified early and I won’t have to repeat tests unnecessarily.
Explain the purpose of different tests and what you hope to learn. Testing can be very physically and
emotionally challenging. It would help me to know the purpose of the test, how long it will take and
what you expect to learn from the process. I would also appreciate the option of breaks during longer
tests and an opportunity to ask questions.
Give me tools for living with this disease. Please don’t give me my diagnosis and then leave me alone to
confront it. I need to know what will happen to me, what medical treatments are available, and what
support and resources are offered through the Alzheimer’s Association® and my community.
Work with me on a plan for living a quality life. Medication may help modify some of my neurological
symptoms, but I am also interested in recommendations for keeping myself as healthy as possible
through diet, exercise and social engagement.
Recognize that I am an individual and the way I experience this disease is unique. This disease affects
each person in different ways and at a different pace. Please be sure to couch your explanation of how
this disease may change my life with this in mind.
Alzheimer’s is a journey, not a destination. Treatment doesn’t end with the writing of a prescription.
Please continue to be an advocate — not just for my medical care but for my quality of life as I continue
to live with Alzheimer’s disease.
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Appendix F: NICE Guideline for Prevention of Delirium
Source: O'Mahony R, Murthy L, Akunne A, Young J; Guideline Development Group. Synopsis of the National
Institute for Health and Clinical Excellence guideline for prevention of delirium. Ann Intern Med. 2011 Jun
7;154(11):746-51. Available here.

1. Ensure that persons at risk for delirium are cared for by a team of health care professionals who are
familiar with the person at risk. Avoid moving persons within and between wards or rooms unless
absolutely necessary.
2. Give a tailored, multicomponent intervention package. Within 24 hours of hospitalization, assess
persons at risk for clinical factors contributing to delirium. On the basis of the results of this
assessment, provide a multicomponent intervention tailored to the person’s individual needs and
care setting.
3. The tailored, multicomponent intervention package should be delivered by a multidisciplinary team
trained and competent in delirium prevention.
4. Address cognitive impairment or disorientation by providing appropriate lighting and clear signage,
ensuring that a clock (consider providing a 24-hour clock in the critical care unit) and a calendar are
easily visible to the person at risk; talking to the person to reorient them by explaining where they
are, who they are, and what your role is; introducing cognitively stimulating activities (for example,
reminiscence); and facilitating regular visits from family and friends.
5. Address dehydration and constipation by ensuring adequate fluid intake to prevent dehydration by
encouraging the person to drink—consider offering subcutaneous or intravenous fluids, if necessary,
and taking advice when managing fluid balance in persons with comorbid conditions (for example,
heart failure or chronic kidney disease).
6. Assess for hypoxia and optimize oxygen saturation, if necessary, as clinically appropriate.
7. Address infection by looking for and treating infection, avoiding unnecessary catheterization, and
implementing infection-control procedures in line with the NICE clinical guideline on infection
control (13).
8. Address immobility or limited mobility through the following actions: Encourage persons to mobilize
soon after surgery and walk (provide appropriate walking aids that are accessible at all times) and
encourage all persons, including persons who are unable to walk, to carry out active, range-ofmotion exercises.
9. Address pain by assessing for pain; looking for nonverbal signs of pain, particularly in persons with
communication difficulties (for example, persons with learning difficulties or dementia or persons on
a ventilator or who have a tracheostomy); and initiating and reviewing appropriate pain
management in any person in whom pain is identified or suspected.
10. Carry out a medication review for persons receiving several drugs, taking into account both the type
and the number of medications.
11. Address poor nutrition by following the advice given in the nutrition support in adults section in the
NICE clinical guideline and ensuring that dentures fit properly in persons who have them.
12. Address sensory impairment by resolving any reversible cause of the impairment, such as impacted
ear wax, and ensuring hearing and visual aids are available to and used by persons who need them,
and check that such aids are in good working order.
13. Promote good sleep patterns and sleep hygiene by avoiding nursing or medical procedures during
sleeping hours, if possible; scheduling medication rounds to avoid disturbing sleep; and reducing
noise to a minimum during sleep periods.
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